| Name | Title | Contact Details |
|---|---|---|
Patrick Baumhof |
Senior Vice President of Technology | Profile |
Mariola Fotin-Mleczek |
Chief Technology Officer | Profile |
Mariola Fotin-Mleczek |
Chief Technology Officer | Profile |
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
Founded in 2011, PANTHERx Rare is a specialty pharmacy solely focused on rare and orphan diseases, distributing several orphan products and providing access and support services to those needing them most. Known as The Rare Disease Pharmacy®, PANTHERx transforms lives by delivering therapeutic breakthroughs, clinical excellence, personalized support, and a range of access solutions to people living with rare and devastating conditions. While each rare condition affects few people, together all rare diseases impact an estimated 25 to 30 million Americans. Currently over 7,000 rare diseases have been identified and more than 90% of rare diseases are still without an FDA-approved treatment. Changes in federal policy and advances in science have led to a surge in FDA orphan drug approvals, providing tremendous hope to the rare disease community. PANTHERx is a dual-accredited specialty pharmacy, holding distinctions in rare disease including the Accreditation Commission for Health Care (ACHC) Distinction in Orphan Drugs and Utilization Review Accreditation Commission (URAC) Rare Disease Center of Excellence. As a pharmacy focused on patient satisfaction, PANTHERx is the seven-time winner of the prestigious MMIT Patient Choice Award, including the 2024 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania and is licensed in all 50 states and US territories. #ReinventingSpecialty #RevolutionizingPharmacy #RedefiningCare #DefiningRarePharmacy #TheRareDiseasePharmacy
At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.
We are advocates, not just providers. Leading health plans and patients to better outcomes through a broad range of medication therapy management (MTM) programs. Empowering connections that matter. Mirixa is the leading provider of MTM and targeted, pharmacist-delivered services to health plans. An MTM pioneer, we`ve been building connections since 2006 - harnessing the knowledge and skills of pharmacists to engage more patients and deliver measureable results. We have the largest and most comprehensive pharmacy services network in North America. And we create leading edge programs that reach beyond Medicare Part D compliance, helping health plans of all types deliver a more focused patient experience and positive outcome, while potentially reducing total healthcare costs. Our goal is your goal: to ultimately empower every patient to live a fuller, healthier life.
Spectrum Sciences is a California, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.